Study of the Transmission of Anti-interferon Type 1 Alpha Autoantibodies From Mother to Child Via the Placental Barrier (Pregiferon)

CerbaXpert

Status

Not yet enrolling

Conditions

Woman Suffering From a Pathology Frequently Associated With the Presence of These Anti-autoantibodies Type-I Interferons

Treatments

Other: Pregiferon

Study type

Interventional

Funder types

Other

Identifiers

NCT06371235

2024-A00739-38

Details and patient eligibility

About

The main objective of the study is to evaluate the frequency of placental transfer of self-Ab directed against the mother's IFN alpha in the newborn, in all women suffering from a pathology frequently associated with the presence of these autoantibodies and in those seropositive during the pregnancy.

Enrollment

250 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Pregnant woman over 18 years old
Woman whose gestational age is less than 30 weeks.
Having agreed to carry out an assay of anti-IFN alpha IgG auto-Ac before 30 weeks
Give birth in the inclusion center
Suffering from a pathology frequently associated with the presence of these anti-autoantibodies IFN alpha (lupus, severe COVID-19, myasthenia gravis, incontinentia pigmenti, hypoparathyroidism, adrenal insufficiency, diffuse candidiasis, Biermer's disease, dysthyroidism, type 1 diabetes, celiac disease, auto-thyroid disease immune system such as Graves' disease, Hashimoto's thyroiditis) or knowing its positive anti-IFN alpha autoantibody status
Affiliated with the Social Security system

Exclusion criteria

Patient who underwent a blood transfusion less than 2 months ago
Patient who received an organ transplant
Patient undergoing immunotherapy, stem cell therapy and/or other malignancy maternal, under heavy treatment (chemotherapy) less than 6 months before inclusion